ExpressionEdits

ExpressionEdits is a biotechnology firm established to address inefficiencies in protein production for therapeutic and industrial applications. Founded in 2021 by Dr. Kärt Tomberg, Professor Allan Bradley, and Dr. Liliana Antunes, the company originated from research conducted at the University of Cambridge. The founding concept emerged from Dr. Tomberg's postdoctoral work, where she repeatedly faced research delays due to inefficient protein expression systems and realized these same issues created significant costs for pharmaceutical companies. Dr. Tomberg, the CEO, has a background in genetic engineering and bioinformatics, with a PhD in Human Genetics from the University of Michigan. Co-founder Dr. Liliana Antunes, the Head of Product Testing, holds a PhD in Stem Cell Biology from the University of Cambridge and specializes in functional genomics and gene therapy.

The company's core business revolves around its proprietary 'intronization' technology, which redesigns artificial genes (transgenes) to better mimic their natural counterparts, thereby improving protein expression levels. ExpressionEdits utilizes a computational platform called the Genetic Syntax Engine, which employs artificial intelligence and machine learning to analyze biological data and strategically incorporate introns—non-coding DNA sequences—into transgene designs. This process enhances the stability and export of RNA, enabling the production of complex proteins that have historically been difficult or impossible to manufacture at scale. The business model includes developing an internal pipeline of protein-based therapeutics and forming commercial partnerships. A significant milestone was a partnership and licensing agreement with Boehringer Ingelheim to develop novel gene therapies for two undisclosed targets. The company primarily serves the cell and gene therapy markets, a sector valued at over $20 billion.

The company's primary focus is on recombinant proteins and gene therapies that face manufacturing challenges with existing technologies. By improving protein yields, the technology allows for lower therapeutic doses, which can minimize toxicity and expand design options for therapies that were previously limited by poor expression. A key achievement was securing a $13 million seed funding round in May 2024, co-led by Octopus Ventures and redalpine, to accelerate preclinical studies and pipeline development. This funding enables ExpressionEdits to tackle the production of therapeutics for which the industry is currently reliant on human plasma, a practice with risks related to disease transmission and supply chain fragility.

Keywords: intronization technology, protein expression, gene therapy, genetic syntax engine, AI in biotechnology, transgene design, recombinant protein production, cell therapy, preclinical studies, therapeutic proteins, University of Cambridge spin-out, Kärt Tomberg, Liliana Antunes, Allan Bradley, Boehringer Ingelheim partnership, genetic medicine, biopharmaceutical development, computational gene editing, hard-to-express proteins, DNA medicines, antibody manufacturing